Total | 112 | | |
Age | | | |
Mean (SD): 61.2 (13.6) years | | | |
Range: 24–95 | | | |
MAC stage | | | 0.12 |
B1 | 11 (9.8) | 4.09 (2.34) | |
B2 | 52 (46.4) | 4.38 (3.03) | |
C1 | 3 (2.7) | 4.33 (3.51 | |
C2 | 36 (32.1) | 5.50 (3.73 | |
D | 10 (8.9) | 6.0 (4.52) | |
AJCC group | | | 0.12 |
Stage I | 11 (9.8) | 4.09 (2.34) | |
Stage IIA | 52 (46.4) | 4.38 (3.03) | |
Stage IIIA | 3 (2.7) | 4.33 (3.51) | |
Stage IIIB | 36 (32.1) | 5.50 (3.73) | |
Stage IV | 10 (8.9) | 6.0 (4.52) | |
Lymph node involvement | | | 0.06 |
Negative | 65 (58) | 4.43 (3.07) | |
<4 | 30 (27) | 5.13 (4.18) | |
⩾4 | 17 (15) | 6.0 (2.71) | |
Distant metastasis | | | 0.51 |
Negative | 102 (91) | 4.74 (3.25) | |
Positive | 10 (8.9) | 6.0 (4.52) | |
Venous invasion | | | 0.02 |
Negative | 98 (87) | 4.63 (3.37) | |
Positive | 14 (12) | 6.42 (3.10) | |
Lymphatic invasion | | | 0.01 |
Negative | 73 (65) | 4.32 (3.24) | |
Positive | 39 (35) | 5.84 (3.43) | |
Perineural invasion | | | 0.11 |
Negative | 75 (67) | 4.70 (3.68) | |
Positive | 37 (33) | 5.16 (2.66) | |
Tumour grade | | | 0.22 |
Well differentiated | 20 (18) | 4.45 (2.76) | |
Moderately differentiated | 63 (56) | 5.52 (3.77) | |
Poorly differentiated | 29 (26) | 3.68 (2.46) | |